Core Viewpoint - The announcement details the completion of share reduction plans by major shareholders of Kory Technology, indicating a decrease in their ownership stakes without affecting the company's control or governance structure [1][6]. Shareholder Reduction Summary - Colibri Technologies PTE LTD reduced its shareholding from 38.1003% to 37.1003%, selling 4,176,400 shares at an average price of 17.89 CNY per share, totaling approximately 74.67 million CNY [2][3][4]. - Hua Miao Investment reduced its stake from 15.4089% to 14.9713%, selling 1,827,702 shares at an average price of 17.91 CNY per share, totaling approximately 32.69 million CNY [2][3][4]. - Eagle Investment sold 1,200,000 shares at an average price of 15.87 CNY per share, reducing its stake from 7.5077% to 7.2203%, totaling approximately 19.04 million CNY [2][3][4]. Total Reduction Impact - The total shares reduced by the three entities amounted to 7,204,100 shares, with a total reduction value of approximately 126 million CNY [3][4]. Company Background - Kory Technology was listed on the Shenzhen Stock Exchange on July 26, 2019, with an initial issuance of 41 million shares at a price of 15.10 CNY per share, raising a total of 619 million CNY [6][7]. - The company’s actual controller is Phua Lee Ming, who has served as chairman since October 2013 [6].

百诚医药：控股股东拟5000万元~1亿元增持公司股份 每经记者｜王琳 每经编辑｜马子卿 并购重组 博瑞医药：拟认购苏州极客基因新增注册资本 博瑞医药公告，公司拟以2000万元认购苏州极客基因科技有限公司新增注册资本，增资后将取得极客基 因4.1667%股权。此次交易构成关联交易，未构成重大资产重组。 西部黄金：拟以16.55亿元收购新疆美盛100%股权 西部黄金公告，公司拟以自有资金和贷款，收购公司控股股东新疆有色持有的新疆美盛矿业有限公司 100%股权。交易价格16.55亿元，与账面值相比的溢价为1421.66%。 津投城开：拟购买股权并定增募集配套资金 津投城开公告，拟通过资产置换、发行股份及支付现金方式购买天津津能股份有限公司100%股份、天 津市热力有限公司100%股权和天津港益供热有限责任公司100%股权，并向不超过35名特定投资者发行 股份募集配套资金。 增减持 恒邦股份公告，公司于近日收到山东证监局出具的《关于对山东恒邦冶炼股份有限公司采取责令改正措 施的决定》和《关于对刘元辉采取监管谈话措施的决定》。主要内容为公司副总经理刘元辉因涉嫌犯罪 被采取取保候审的刑事强制措施，公司未及时披露相关信息， ...

恩捷股份(002812.SZ)公告称，公司股东合力投资及上海恒邹计划在未来三个月内，通过集中竞价交易 和大宗交易方式减持公司股份。合力投资拟减持不超过5,063,430股（占公司总股本的0.52%），上海恒 邹拟减持不超过6,460,660股（占公司总股本的0.67%）。减持原因为部分股东的个人资金需求。减持期 间为公告披露日起15个交易日后的3个月内。 ...

Policy Developments - The National Health Commission of China is taking measures to ensure blood supply in key areas and important time periods due to a noticeable decline in voluntary blood donations, influenced by factors such as aging population and lifestyle changes [2] - In 2024, the total blood supply in China is expected to decrease year-on-year, with a cumulative blood allocation of 3.613 million units, including 583,000 units allocated between provinces, representing a 35.1% increase [2] Drug and Medical Device Approvals - Kelun Pharmaceutical announced that its subsidiary has received drug registration approval for "Cefazolin Sodium/ Sodium Chloride Injection," which is packaged in a dual-chamber bag and is suitable for emergency treatment [4] - *ST Sailong's subsidiary has obtained a drug registration certificate for Famotidine Injection, classified as a Category A drug under the national medical insurance list, primarily used for treating upper gastrointestinal bleeding [5] Capital Market Activities - Borui Pharmaceutical plans to invest 20 million yuan to subscribe to the increased registered capital of Geek Gene Technology, acquiring a 4.1667% stake in the company [7] Industry Developments - Eli Lilly announced the launch of the multi-dose prefilled pen for Tirzepatide Injection in China, aimed at addressing the needs of the growing number of diabetes and obesity patients [9] - The adult overweight rate in China is 34.3%, with an obesity rate of 16.4%, highlighting the increasing demand for weight management treatments [9] - In the first quarter of this year, Tirzepatide contributed $6.15 billion in revenue to Eli Lilly, accounting for approximately 48% of the company's total revenue [10] - Hanyu Pharmaceutical has completed the enrollment of all subjects for the Phase III clinical trial of Semaglutide Injection for weight management, currently in the follow-up phase [11] Shareholder Actions - Nine Strong Bio's major shareholder completed a share reduction plan, reducing their holdings from 30,969,636 shares to 30,769,636 shares, a decrease from 5.30% to 5.26% of voting shares [13] - Yifeng Pharmacy's controlling shareholder plans to reduce their stake by up to 2%, amounting to no more than 24,248,336 shares [14]

Core Viewpoint - The stock price of Chaojie Co., Ltd. (301005) has significantly declined following the announcement of a planned share reduction by major shareholders, including the son of the chairman, which may indicate concerns about the company's future performance and valuation [1][3][4]. Group 1: Shareholder Actions - Three shareholders, including Song Yibo, the son of Chairman Song Guandong, plan to collectively reduce their holdings by up to 3.73% of the company's shares, corresponding to a market value of approximately 194 million yuan based on the closing price [1][3]. - Song Yibo intends to reduce his stake by up to 2.38% within three months after the announcement, which would represent a near-total liquidation of his holdings, valued at about 124 million yuan [3]. - The other two shareholders, Taizhou Yuwei Investment Co., Ltd. and Taizhou Wenchao Investment Co., Ltd., plan to reduce their stakes by up to 0.85% and 0.5%, respectively [3]. Group 2: Stock Performance - Chaojie Co., Ltd. experienced a significant stock price increase of 82.28% from April 9 to June 6, 2023, before facing a sharp decline [3]. - The stock reached an all-time high of 48.48 yuan per share on June 10, 2023, but subsequently fell by 9.38% on the same day and continued to decline by 4.93% the following day [3]. Group 3: Financial Performance - Since its listing in June 2021, Chaojie Co., Ltd. has seen a continuous decline in annual net profits, with revenues increasing from approximately 394 million yuan in 2021 to 630 million yuan in 2024, while net profits dropped from about 75.86 million yuan to 10.62 million yuan in the same period [5]. - In the first quarter of 2025, the company reported revenues of approximately 189 million yuan, a year-on-year increase of 38.36%, and a net profit of about 15.99 million yuan, up 27.18% year-on-year [6]. - The company's debt-to-asset ratio has been rising annually, increasing from 12.08% in 2021 to 37.43% in 2024 [6].

罗欣药业（002793）公告，持股5%以上股东方秀宝及其一致行动人方东晖、温岭市大任企业管理有限 公司合计持有公司股份1.32亿股，占剔除回购专用账户股份后的总股本比例12.19%。大任管理计划通过 集中竞价或大宗交易方式减持不超过1044.21万股，占公司总股本比例0.96%，减持期间为公告披露日起 15个交易日后的三个月内。 ...

Core Viewpoint - The company Jinma Amusement (300756) announced that its Vice General Manager and Board Secretary, Zeng Qingyuan, plans to reduce his shareholding by up to 269,500 shares, accounting for 0.17% of the company's total share capital, due to personal financial needs [1] Summary by Relevant Sections - **Shareholding Reduction Plan** - Zeng Qingyuan intends to reduce his holdings through centralized bidding and block trading within three months after the disclosure of the reduction plan [1] - The maximum number of shares to be reduced is 269,500, which represents 0.17% of the total share capital [1] - **Current Shareholding Status** - Zeng Qingyuan currently holds 1,078,400 shares, which is 0.68% of the company's total share capital [1] - **Impact on Company Structure** - The reduction will not lead to any change in the company's control, governance structure, or operational continuity [1]

Core Viewpoint - The report outlines the equity change of Beijing Baiana Qiancheng Film Co., Ltd., indicating that the information disclosure obligor, Liu Dehong, has reduced his shareholding to below 5% as of June 12, 2025, due to personal financial needs [1][4][5]. Group 1: Equity Change Details - The equity change is a result of Liu Dehong's personal financial needs, leading to a planned reduction of up to 9,418,896 shares (1% of total share capital) within a specified period [4][5]. - As of June 12, 2025, Liu Dehong sold 106,218 shares, reducing his total holdings to 47,094,382 shares, which represents 4.99999% of the total share capital [5][6]. - The total reduction in shares from May 13, 2015, to June 12, 2025, amounts to 21,561,618 shares, equating to a 5.06% decrease in ownership [7]. Group 2: Future Plans and Compliance - Liu Dehong may continue to adjust his shareholding within the next 12 months, with plans to potentially increase or further decrease his holdings, adhering to relevant legal disclosure requirements [5][6]. - The report confirms that Liu Dehong does not hold any shares in other listed companies that exceed 5% of their total issued shares [4][6]. - The equity change will not affect the control of the company, as Liu Dehong is not a controlling shareholder or actual controller, ensuring no significant impact on the company's governance or ongoing operations [6][7].

Core Viewpoint - The recent share reduction by Guo Fengming, the controlling shareholder of Kanda, raises concerns about the company's long-term value despite the stock price resilience and positive earnings growth [1][3][4]. Group 1: Share Reduction Details - Guo Fengming's share reduction plan, which was first disclosed on February 17, 2025, involved a maximum reduction of 3% of shares, with a total of 512.26 million shares sold, amounting to approximately 57.39 million yuan [2]. - Since March 2023, Guo has cumulatively reduced 15.33 million shares, cashing out over 203 million yuan, decreasing his holding from 51.92% to 45% while still maintaining control [3]. Group 2: Market Reaction and Institutional Involvement - During the share reduction period, Kanda's stock price increased, reaching a high of 12.24 yuan, contrasting with the slight rise of the Shanghai Composite Index [2]. - Institutional investors showed a net buying of 34.14 million yuan on the same day as the reduction, indicating a complex market dynamic of shareholder selling and institutional buying [2]. Group 3: Financial Performance and Operational Concerns - Kanda reported a revenue of 81.26 million yuan in Q1 2025, a year-on-year increase of 17%, with a net profit of 31.98 million yuan, up 20.88%, and a maintained gross margin of 44% [4]. - However, operational efficiency is a concern, with accounts receivable turnover at only 0.19 times and inventory turnover at 0.21 times, indicating low operational efficiency [4]. Group 4: Investor Insights and Strategic Considerations - The situation illustrates the coexistence of shareholder reduction and institutional buying, suggesting that the impact of single signals in the market is diminishing [5]. - Investors should monitor the implementation of policies such as the "Lightweight Development Plan for Rail Transit Equipment" expected at the end of June, which may influence the sector [5]. - The reduction in shareholder numbers, currently at 17,100, down 12% from peak levels, indicates increased concentration of shares, which may heighten stock price volatility [5].

| 项目 | 本报告期 | 上年同期 | 本报告期比上年同 期增减变动幅度 | | --- | --- | --- | --- | | | | | (%) | | 营业收入 | 102, 233, 732. 21 | 137.499.053.47 | -25. 65 | | 归属于上市公司股东的净利 | 1.610.129.07 | 46, 373, 345. 19 | -96. 53 | | 润 | | | | | 归属于上市公司股东的扣除 | -339.880.24 | 30.554.287.70 | -101. 11 | | 非经常性损益的净利润 | | | | | 经营活动产生的现金流量净 | -42, 215, 871. 67 | 2. 158. 576. 87 | -2.055.73 | | 额 | | | | 2020年至2024年，电魂网络营业收入分别为10.24亿元、9.96亿元、7.91亿元、6.77亿元、5.50亿元，归 属于上市公司股东的净利润分别为3.95亿元、3.39亿元、2.01亿元、5683.79万元、3057.89万元，归属于 上市公司股东的扣除非经常性损益的净利润分别为3. ...